Pluri Inc. · NASDAQ:PLUR
Pluri — Pluristem Therapeutics — Corporate Update (December 2020)
15 slides from Pluri's corporate update, Dec 9, 2020
Slide 1: Pluristem Conference Call
December 9 , 2020 PLURISTEM CONFERENCE CALL Inspired by Life
Slide 2: Forward-looking statements
2 This presentation contains express or implied forward - looking statements within the Private Securities Litigation Reform Act of 1995 and other U . S . Federal securities laws . For example, we are using forward - looking statements when we discuss that we expect topline clinical results during t
Slide 3: Critical Limb Ischemia (CLI) Interim Analysis
3 Critical Limb Ischemia ( CLI) Interim Analysis 3 • The company's Phase III CLI study is unlikely to meet its primary endpoint by the time of the final analysis • CLI study population has experienced a substantial low number of events different from what is known in literature*. The lower than anti
Slide 4: Clinical Pipeline
4 Clinical Pipeline *Via FDA Animal Rule PRECLINICAL PHASE I PHASE II PHASE III FUNDING Partner LOCATION INDICATION FOCUS PRODUCT PLX - PAD Muscle Injuries Inflammatory Diseases Muscle Regeneration following Hip Fracture U.S., Europe, Israel ARDS due to COVID - 19 Graft Versus Host Disease U.S., Eur
Slide 5: Clinical readouts expected within the coming calendar year
5 ARDS associated with COVID - 19 Phase II HTC Phase I Muscle regeneration following HIP fracture Phase III Clinical readouts expected within the coming calendar year Pluristem ’ s One - Platform Multiple - Applications Strategy
Slide 6: Ongoing Muscle Regeneration Following Hip Fracture - Phase III Study
Ongoing Muscle Regeneration Following Hip Fracture - Phase III Study 6 * Kannus P, Parkkari J, Sievänen H, et al. Epidemiology of hip fractures **Simran Mundi, et. al. 2014 ***Jorma Panula, et. al. 2011 • Worldwide, the total number of hip fractures is expected to surpass 6 million by the year 2050
Slide 7: PLX-PAD in Severe ARDS Associated with COVID-19
7 One of the most common causes of death from COVID - 19 PLX - PAD cells have immunomodulatory and cytoprotective properties which may play a meaningful role in mitigating the tissue - damaging effects of COVID - 19 on the lungs Mechanism of Action Severe ARDS (Acute Respiratory Distress Syndrome) A
Slide 8: COVID-19 Data: Compassionate Use Results
of patients were discharged alive from the hospital compared to 3.3 % ( 38 out of 1151 patients)* Survival rate 87.5 % 75.0 % COVID - 19 Data of patients were off any mechanical ventilation 62.5 % Encouraging results from Compassionate Use Programs in the U.S. & in Israel 28 - day follow - up for th
Slide 9: Phase I – Incomplete Hematopoietic Recovery Following HCT
Phase I – Incomplete Hematopoietic Recovery Following Hematopoietic Cell Transplantation (HCT) • Initial results from 19 patients treated with PLX - R 18 demonstrated*: • Significant clinical improvements in Hb, ANC, and PLT among the high - dose cohort • PLX - R 18 was found to be safe and well - t
Slide 10: In-House Commercial-Scale Manufacturing Facility
In - House Commercial - Scale Manufacturing Facility Manufacturing Technology: • Patented technology platform with diverse range of applications • Marketing scale 3 D technology applied in all of our clinical trials • Cost - effective , market - ready industrialized platform • Automated , efficient
Slide 11: Full Vertical Solution: From Raw Material to the Patient's Bed
Thawing Device Storage Advanced cold chain logistics Quality Control Manufacturing Cell Harnessing Process D ev elopment Clinical D ev elopment Cold Chain GMP Manufacturing 1 placenta can treat ~ 20,000 patients Regulatory Approvals in EU, USA, Israel, South Korea & Japan IM Injection Shipment Contr
Slide 12: Financials
12 Financials 12 Cash: ~$ 53 million (as of Sept. 30 , 2020 ) EIB non - dilutive financing agreement: First tranche of € 20 expected during H 1 of 2021 calendar year * Extensive support by non - dilutive grants and government funding Solid financial position to fund the ongoing clinical studies of P
Slide 13: Investment summary: off-the-shelf placenta-derived cell products
13 Off - the - shelf placenta - derived cell products • No blood or tissue matching required • Young, highly potent and ethical source Platform technology with advanced clinical pipeline • Development for muscle injuries, inflammatory diseases and hematological deficiencies • Diverse clinical pipeli
Slide 14: Q&A
14 Q& A
Slide 15: Thank you
15 Thank you www.Pluristem.com Investor.relations@Pluristem.com Israel + 972 - 74 - 710 - 8600 U.S. + 1 - 347 - 973 - 2098 Germany + 49 - 30 - 2215 - 0786
Pluristem Therapeutics — Corporate Update (December 2020) on 6ix